ArticleThe Journal of clinical investigation2013
Rice-based oral antibody fragment prophylaxis and therapy against rotavirus infection.
Article in The Journal of clinical investigation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 89 citations in OpenAlex.
- Review
- Recent Advancements in Non-Invasive Vaccination Strategies.Vaccines · 2025Review
- Biotechnological Interventions for the Production of Subunit Vaccines Against Group A Rotavirus.Cell biochemistry and function · 2024Review
- Article
- A Nanobody of PEDV S1 Protein: Screening and Expression inBiomolecules · 2024Article
- Lactobacilli as a Vector for Delivery of Nanobodies against Norovirus Infection.Pharmaceutics · 2022Article
- Development of spirulina for the manufacture and oral delivery of protein therapeutics.Nature biotechnology · 2022Article
- Research progress and applications of nanobody in human infectious diseases.Frontiers in pharmacology · 2022Review
- Anti-CfaE nanobodies provide broad cross-protection against major pathogenic enterotoxigenic Escherichia coli strains, with implications for vaccine design.Scientific reports · 2021Article
- Therapeutic Applications of Functional Nanomaterials for Prostatitis.Frontiers in pharmacology · 2021Review
- Development of Antibody-Fragment-Producing Rice for Neutralization of Human Norovirus.Frontiers in plant science · 2021Article
- Unprecedented enhancement of recombinant protein production in sugarcane culms using a combinatorial promoter stacking system.Scientific reports · 2020Article
- Inhibition of invasive salmonella by orally administered IgA and IgG monoclonal antibodies.PLoS neglected tropical diseases · 2020Article
- Development of Systems for the Production of Plant-Derived Biopharmaceuticals.Plants (Basel, Switzerland) · 2019Review
- A nanobody targeting the translocated intimin receptor inhibits the attachment of enterohemorrhagic E. coli to human colonic mucosa.PLoS pathogens · 2019Article
- Review
- Viral gastroenteritis.Lancet (London, England) · 2018Review
- Therapeutics and Immunoprophylaxis Against Noroviruses and Rotaviruses: The Past, Present, and Future.Current drug metabolism · 2018Review
- Edible plants for oral delivery of biopharmaceuticals.British journal of clinical pharmacology · 2017Review
- Single-Domain Antibodies As Therapeutics against Human Viral Diseases.Frontiers in immunology · 2017Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
18 authors at 6 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rotavirus-induced diarrhea is a life-threatening disease in immunocompromised individuals and in children in developing countries. We have developed a system for prophylaxis and therapy against rotavirus disease using transgenic rice expressing the neutralizing variable domain of a rotavirus-specific llama heavy-chain antibody fragment (MucoRice-ARP1). MucoRice-ARP1 was produced at high levels in rice seeds using an overexpression system and RNAi technology to suppress the production of major rice endogenous storage proteins. Orally administered MucoRice-ARP1 markedly decreased the viral load in immunocompetent and immunodeficient mice. The antibody retained in vitro neutralizing activity after long-term storage (>1 yr) and boiling and conferred protection in mice even after heat treatment at 94°C for 30 minutes. High-yield, water-soluble, and purification-free MucoRice-ARP1 thus forms the basis for orally administered prophylaxis and therapy against rotavirus infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.